Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.94 USD | +10.86% | +18.29% | +26.80% |
Financials (USD)
Sales 2024 * | 24.2M | Sales 2025 * | 83.79M | Capitalization | 701M |
---|---|---|---|---|---|
Net income 2024 * | -200M | Net income 2025 * | -201M | EV / Sales 2024 * | 29 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 8.37 x |
P/E ratio 2024 * |
-2.54
x | P/E ratio 2025 * |
-2.83
x | Employees | 285 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.44% |
Latest transcript on Lexicon Pharmaceuticals, Inc.
1 day | +10.86% | ||
1 week | +18.29% | ||
Current month | +14.12% | ||
1 month | +11.49% | ||
3 months | -13.78% | ||
6 months | +70.18% | ||
Current year | +26.80% |
Managers | Title | Age | Since |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 14-07-06 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 98-12-31 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-08-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01-01-31 |
Ray Debbane
CHM | Chairman | 69 | 07-07-31 |
Director/Board Member | 65 | 07-08-27 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +10.33% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 1.94 | +10.23% | 3,365,024 |
24-06-04 | 1.76 | +0.57% | 1,740,387 |
24-06-03 | 1.75 | +2.94% | 2,343,281 |
24-05-31 | 1.7 | 0.00% | 1,760,801 |
24-05-30 | 1.7 | +3.66% | 1,058,986 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.80% | 701M | |
+18.72% | 125B | |
+14.53% | 109B | |
-2.88% | 24.74B | |
+4.60% | 22.67B | |
-9.81% | 18.14B | |
-41.04% | 16.67B | |
-11.83% | 16.64B | |
+1.46% | 13.45B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- LXRX Stock